Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

Mutations in Kirsten rat-sarcoma (KRAS) are well appreciated to be major drivers of human cancers through dysregulation of multiple growth and survival pathways. Similar to many other non-kinase oncogenes and tumor suppressors, efforts to directly target KRAS pharmaceutically have not yet materializ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebi, Hiromichi, Faber, Anthony C, Engelman, Jeffrey A, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317830/
https://www.ncbi.nlm.nih.gov/pubmed/24612015
http://dx.doi.org/10.1111/cas.12383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317830/
https://www.ncbi.nlm.nih.gov/pubmed/24612015
http://dx.doi.org/10.1111/cas.12383

Ejemplares similares